What Кселода Treats: Main Uses and Benefits

Capecitabine (Кселода) is a systemic agent primarily used in situations involving malignant tumor activity. The medicine is used alone or may be part of management in combination with other agents for treating specific solid tumors.

Treatment for Key Gastrointestinal and Breast Cancers

This medication is used across conditions presenting with acute episodes, addressing uncontrolled tumor growth. Capecitabine is a core therapy for colorectal cancer (colon and rectal cancer), gastric (stomach) and esophageal cancers, and advanced or metastatic breast cancer. The primary therapeutic benefit supports the patient during difficult episodes by easing distress associated with the malignancy.

In the phase after surgical removal of a primary tumor, it is applied for managing the risk of the cancer returning and supports general well-being during symptomatic phases. The unique oral tablet formulation provides systemic support. This approach may help patients receive supportive, continuous treatment outside of a clinic setting, which assists with maintaining daily routines.

This systemic approach provides an oral route for therapy, which assists with maintaining functional stability during treatment and helps improve day-to-day comfort.

Quick Fact: Relief for Uncontrolled Tumor Growth
Primary Therapeutic Area: Applied across domains where additional symptomatic support is needed for conditions marked by increased physiological stress.
Key Context: Relevant in clinical settings that involve acute or unstable symptom patterns, such as those following surgical procedures or during established phases of the condition.

The eligibility for using Xeloda (capecitabine) is strictly defined by regulatory bodies and is highly dependent on a patient's genetic status, organ function, and current physical state.

Contraindications and Restrictions

Classification	Rule
Absolute Contraindication	Patients with severe renal impairment (creatinine clearance below 30 mL/min) must not use Xeloda. It is also forbidden for patients with known complete dihydropyrimidine dehydrogenase (DPD) deficiency due to the risk of life-threatening toxicity. Additionally, use is forbidden for patients with known hypersensitivity to capecitabine, 5-fluorouracil (5-FU), or related antivirals (e.g., brivudine).
Mandatory Dose Adjustment	Patients with moderate renal impairment (CrCl 30 to 50 mL/min) are eligible, but require a mandatory starting dose reduction to 75% of the standard dose, as stated in the label.
Special Populations	The drug is contraindicated during pregnancy and breastfeeding must be discontinued. Safety and efficacy have not been established in children and adolescents. Patients aged 60 and older are at a greater risk for severe adverse reactions and require careful monitoring.

Interactions with other medicines and products

Interaction Severity Classification	Interacting Agents
Contraindicated	Sorivudine and chemically related analogues (e.g., Brivudine)
Clinically Significant	Coumarin-derivative Anticoagulants (Warfarin, Phenprocoumon), Phenytoin, Allopurinol, Leucovorin

The official regulatory profile for Кселода establishes several constraints concerning co-administered substances. Co-administration with the Dihydropyrimidine Dehydrogenase (DPD) inhibitor Sorivudine or its related analogues is strictly prohibited. This restriction exists because these agents block the enzyme required to clear the drug's active form, resulting in a severe, potentially fatal, increase in drug exposure.

A clinically significant interaction occurs with Coumarin-derivative Anticoagulants like Warfarin. The regulatory description attributes this interaction to the inhibition of the CYP2C9 enzyme by Кселода or its metabolites. This pharmacokinetic effect increases the anticoagulant's systemic exposure, leading to marked elevations in Prothrombin Time (PT) and International Normalized Ratio (INR), which requires close regulatory monitoring.

Other interactions include co-administration with Phenytoin, which may lead to an increase in its plasma concentration. Concomitant use with Allopurinol should be avoided, as regulatory documents note a potential for decreased clinical efficacy. Additionally, the medicine must be taken with food or within 30 minutes after a meal due to its documented effect on absorption characteristics. Patients aged 60 years or older are officially noted to have a higher risk of coagulopathy when combined with Vitamin K antagonists.

Tumor-Targeted Prodrug Activation

The mechanism begins with Capecitabine acting as an inactive prodrug, which is sequentially converted by three different enzymes into the active cytotoxic agent, 5-Fluorouracil (5-FU). Crucially, the final activating enzyme, Thymidine Phosphorylase (TP), is often concentrated within cellular populations, allowing for the majority of the active drug to be generated in situ. This strategic, localized activation is the core physiological mechanism that focuses cytotoxic activity at the target site.

---

Dual Antimetabolite Action on Genetic Synthesis

The generated 5-FU acts as an antimetabolite, engaging two distinct pathways that interfere with core cellular processes. Primarily, it is converted into FdUMP, which irreversibly inhibits the enzyme Thymidylate Synthase (TS), effectively blocking the production of a critical DNA building block. Secondarily, another metabolite, FUTP, is mistakenly incorporated into RNA, damaging its function. This dual blockade of genetic synthesis is the ultimate molecular cascade that induces apoptosis (cell death) in cells characterized by a high rate of division.

How Кселода (Capecitabine) is Used: Administration Guidelines

Кселода is an oral chemotherapy medicine administered according to cyclic schedules. The administration guidelines focus on the route of intake, the dosing schedule, and specific conditions for use.

Administration Route and Form

• Route: The only approved route of administration is Oral (by mouth), using film-coated tablets in 150 mg and 500 mg strengths.
• Intake Conditions: Tablets must be swallowed whole with water and must not be crushed or cut. To ensure proper absorption, each dose must be taken within 30 minutes after the completion of a meal (e.g., breakfast and dinner).

---

Standard Dosing Regimens and Schedules

Treatment with capecitabine is structured around a 21-day cycle and is individualized based on the patient’s Body Surface Area (BSA):

Regimen Type	Standard Starting Dose (Twice Daily)	Administration Schedule (within 21-Day Cycle)
Monotherapy	1250 mg/m^2 BID	Days 1 to 14, followed by a 7-day rest period
Combination Therapy	625 mg/m^2 to 1000 mg/m^2 BID	Varies based on partner drug; often Days 1 to 14

The total daily dose is divided and taken twice daily (BID), approximately 12 hours apart. For adjuvant treatment, the course is generally completed after 6 months (8 cycles).

---

Population-Specific Adjustments

Guidelines require starting dose adjustments for certain patient groups. Specifically, patients with moderate renal impairment (creatinine clearance 30-50 mL/min) must have their starting dose reduced to 75% of the standard regimen. Once a dose has been reduced due to an adverse event, it should not be increased later.

Research Evidence / Overview of Studies for Кселода

Evidence for Use in Colorectal Cancer

Research exploring the use of Кселода (Capecitabine) was conducted across different scenarios for colorectal cancer (cancer of the colon and rectum). The research base includes extensive Randomized Clinical Trials (RCTs), which are comparative studies often used to establish evidence. Studies were applied both when the cancer has spread (the metastatic setting) and after a primary tumor had been surgically removed (the adjuvant setting).

Studies reported measurements related to survival and disease progression endpoints in the study groups that included Кселода. Research describes outcomes that were measured during the study period across different protocols. Research highlights that findings describe group patterns and do not serve as predictions for personal outcomes.

Evidence for Use in Advanced or Metastatic Breast Cancer

The evidence base for Кселода in advanced or metastatic breast cancer includes Randomized Clinical Trials and smaller studies. These investigations primarily focused on patients whose cancer had already been treated with other common chemotherapy agents, such as taxanes or anthracyclines.

The studies monitored outcomes related to Overall Survival and Progression-Free Survival. Research also examined patient-reported outcomes, and Clinical Benefit Response, which was studied using measures like reported pain levels and a patient’s overall functional status. Findings describe patterns observed in the studies related to these measured outcomes in the observed populations.

Evidence for Use in Gastric and Esophageal Cancers

Research has explored the use of Кселода in combination with other medicines for stomach (gastric) and esophageal cancers. The research primarily involves Phase III Randomized Clinical Trials where Кселода was evaluated as a component of a multi-drug regimen.

The studies monitored endpoints such as Overall Survival and the Tumor Response Rate. Research also examined outcomes related to functional status, such as the duration of symptom-free periods and functional stability during the treatment. The findings describe group patterns observed under the specific conditions of those trials.

What is Still Uncertain About Кселода's Research Base

There are several areas where the research landscape remains uncertain or limited. Long-term effects are not fully established across all indications, and there is limited information regarding outcomes after many years of follow-up for every specific combination protocol. Evidence heterogeneity was observed across studies, and comparative evidence with the newest classes of cancer drugs is still emerging.

Key Studies & References Efficacy and safety of capecitabine-based first-line chemotherapy in advanced or metastatic breast cancer: a meta-analysis of randomised controlled trials

Common questions about Кселода (FAQ)

---

Q: Does this medicine make you sleepy?

Official product information indicates that side effects like dizziness and somnolence (sleepiness) are listed as potential risks. If these effects occur, regulatory documents advise caution regarding activities that require alertness, such as driving or operating machinery.

---

Q: Can I take this for migraines?

The official product label indicates the medicine's approved uses, which include Juvenile Rheumatoid Arthritis (JRA) and acute pain management. However, the capsule form is not specifically indicated in regulatory documents for the acute treatment of migraine.

---

Q: Is it safe to take this medicine long-term?

Official warnings mention that risks associated with this type of medicine, particularly cardiovascular risks, may increase with higher dosage and longer duration of use. Regulatory documents stress using the lowest effective daily dose and the shortest duration possible. The patient's continuing need for the medicine should be re-evaluated periodically by a healthcare professional.

---

Q: Can children 2 years old use it?

The US FDA label indicates that the medicine is approved for the management of the signs and symptoms of Juvenile Rheumatoid Arthritis (JRA) in patients who are 2 years and older. However, it is important to note that the EU's SmPC (Summary of Product Characteristics) states the medicine is not indicated for use in children.

---

How to Store and Dispose of Xeloda (Capecitabine)

Official regulatory documents require that Xeloda tablets be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The container must be kept tightly closed and the medication must be actively protected from moisture and light.

Handling and Disposal

Xeloda is classified as a cytotoxic drug. Applicable special handling and disposal procedures for cytotoxic waste must be followed by professionals. The medication must always be stored out of the reach of children. Any unused or expired product must be disposed of in accordance with local pharmaceutical waste requirements; it should not be discarded in household trash or down the drain.